...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Veterinary Internal Medicine >Serum levetiracetam concentrations after transdermal levetiracetam administration, 3 times daily, to healthy cats
【24h】

Serum levetiracetam concentrations after transdermal levetiracetam administration, 3 times daily, to healthy cats

机译：健康猫经皮左乙拉西坦给药后的血清左乙拉西坦浓度，每天3次

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Repeated oral administration of antiepileptic drugs can be challenging for cat owners, resulting in reduced compliance, poor seizure control, and reduced quality of life for cats. Levetiracetam (LEV) has several properties that make it an appealing drug for transdermal application. Objectives The aims were to (1) determine if transdermal LEV, in a lipophilic, liposomic cream vehicle, resulted in serum concentrations above 5?μg/mL; (2) identify clinical adverse effects; and (3) evaluate the concentration of LEV in a lipophilic liposomic cream at set intervals. Animals Six healthy, client‐owned cats weighing ≤5?kg. Methods Prospective clinical trial. Transdermal LEV was applied to the inner pinna at a dosage of 60?mg/kg (400?mg/mL concentration) at home for 6?days. Day 7, cats were hospitalized for blood sample collection for LEV concentration at times 0 (before dose administration), 0.5, 1, 2, 3, and 4?hours after administration. Results Median (range) timed serum concentrations were 16.6 (8.6‐39.6) μg/mL, 16.1 (6.8‐34.4) μg/mL, 15.4 (10.1‐36.7) μg/mL, 17.4 (9.2‐32.7) μg/mL, 15.1 (8.3‐25.9) μg/mL, and 14.8 (11.9‐28.4) μg/mL, respectively. Adverse events were limited to sedation (1/6 cats) and pinna crusting (1/6 cats). The LEV, in the proposed vehicle, retained concentration above 95% at 400?mg/mL up to 5?weeks. Conclusions and Clinical Importance Thrice daily transdermal LEV resulted in median serum concentrations ≥5?μg/mL throughout the sampling period and clinical adverse events were minimal. Transdermal LEV can provide an alternative for cats resistant to administration of other forms of anticonvulsant medication.
机译：背景对猫主人来说，反复口服抗癫痫药可能是一个挑战，导致顺应性降低，癫痫发作控制不良以及猫的生活质量降低。左乙拉西坦（LEV）具有多种特性，使其成为经皮应用的吸引人的药物。目的目的是（1）确定在亲脂性脂质体乳膏载体中经皮LEV是否导致血清浓度高于5？μg/ mL; （2）确定临床不良反应; （3）以设定的时间间隔评估亲脂性脂质体乳膏中LEV的浓度。动物体重不超过5？kg的六只健康的客户拥有的猫。方法进行前瞻性临床试验。在家中以60？mg / kg（400？mg / mL的浓度）剂量将透皮LEV应用于内耳，持续6天。第7天，在给药后0（给药前），0.5、1、2、3和4小时后的时间，将猫住院收集血样以获取LEV浓度。结果中位（范围）定时血清浓度为16.6（8.6-39.6）μg/ mL，16.1（6.8-34.4）μg/ mL，15.4（10.1-36.7）μg/ mL，17.4（9.2-32.7）μg/ mL，15.1 （8.3-25.9）微克/毫升和14.8（11.9-28.4）微克/毫升。不良事件仅限于镇静（1/6猫）和品纳结s（1/6猫）。在拟议的载体中，LEV在400？mg / mL的浓度下可保持95％以上的浓度，直至5周。结论和临床重要性每天三次经皮LEV可使整个采样期间的血清中浓度≥5？μg/ mL，临床不良事件极少。透皮LEV可以为猫对其他形式的抗惊厥药物的抗药性提供替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号